GENAISSANCE PHARMACEUTICALS JOINS MSI'S FUNCTIONAL GENOMICS CONSORTIUM
19-Feb-2001
Molecular Simulations Inc. (MSI), a
subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP), welcomes Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC), a leader in the field of personalized
medicines, as a charter member of its functional genomics Consortium. As a
Consortium charter member, Genaissance has access to MSI's AtlasBaseä, a
broad collection of available gene sequences with enhanced functional
annotations.
MSI's Functional Genomics Consortium was launched last year to deliver new
automated technology for high-throughput structural proteomics, protein
function assignment, and sequence annotation. Other Consortium members
include Hyseq and Cytoclonal Pharmaceutics.
Dr. Richard Judson, Senior Vice President of informatics at Genaissance,
comments, "Personalized medicine is a new and exciting field with the potential
to have an enormous impact on pharmaceutical development and on human
health. Based upon an initial validation project, we are confident that joining
MSI's Functional Genomics Consortium will make us better equipped to
analyze the functional implications of gene variability. This knowledge will add
another dimension to our ability to predict individual drug responses based on
each person's DNA.
"Dr. Scott Kahn, Senior Vice President Life Sciences at MSI, adds, "We are
excited to be working closely with Genaissance to expand the scope of the
Consortium to include the challenges of pharmacogenetics, characterization of
gene product variants, and the understanding of the functional significance of
SNPs and haplotypes. As we enter the next competitive theater in the
post-genomic era, the higher resolution of information derived from knowledge
of predicted protein structure will give Genaissance a competitive advantage in
their pursuit of personalized medicines."
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
